These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 28720444)

  • 1. Characterization of a spray-dried candidate HPV L2-VLP vaccine stored for multiple years at room temperature.
    Peabody J; Muttil P; Chackerian B; Tumban E
    Papillomavirus Res; 2017 Jun; 3():116-120. PubMed ID: 28720444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mixed Bacteriophage MS2-L2 VLPs Elicit Long-Lasting Protective Antibodies against HPV Pseudovirus 51.
    Yadav R; Zhai L; Kunda NK; Muttil P; Tumban E
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34200586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer.
    Zhai L; Yadav R; Kunda NK; Anderson D; Bruckner E; Miller EK; Basu R; Muttil P; Tumban E
    Antiviral Res; 2019 Jun; 166():56-65. PubMed ID: 30926288
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem HPV L2 peptide offers similar protection in mice to Gardasil-9.
    Zhai L; Peabody J; Pang YS; Schiller J; Chackerian B; Tumban E
    Antiviral Res; 2017 Nov; 147():116-123. PubMed ID: 28939477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized Formulation of a Thermostable Spray-Dried Virus-Like Particle Vaccine against Human Papillomavirus.
    Saboo S; Tumban E; Peabody J; Wafula D; Peabody DS; Chackerian B; Muttil P
    Mol Pharm; 2016 May; 13(5):1646-55. PubMed ID: 27019231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. VLPs displaying a single L2 epitope induce broadly cross-neutralizing antibodies against human papillomavirus.
    Tumban E; Peabody J; Tyler M; Peabody DS; Chackerian B
    PLoS One; 2012; 7(11):e49751. PubMed ID: 23185426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the thermal stability and the protective efficacy of spray-dried HPV vaccine, Gardasil® 9.
    Kunda NK; Peabody J; Zhai L; Price DN; Chackerian B; Tumban E; Muttil P
    Hum Vaccin Immunother; 2019; 15(7-8):1995-2002. PubMed ID: 30883270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today?
    Yadav R; Zhai L; Tumban E
    Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
    Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
    Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M
    J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development.
    Ahmels M; Mariz FC; Braspenning-Wesch I; Stephan S; Huber B; Schmidt G; Cao R; Müller M; Kirnbauer R; Rösl F; Hasche D
    Front Immunol; 2022; 13():1010790. PubMed ID: 36263027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RG2-VLP: a Vaccine Designed to Broadly Protect against Anogenital and Skin Human Papillomaviruses Causing Human Cancer.
    Olczak P; Matsui K; Wong M; Alvarez J; Lambert P; Christensen ND; Hu J; Huber B; Kirnbauer R; Wang JW; Roden RBS
    J Virol; 2022 Jul; 96(13):e0056622. PubMed ID: 35703545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A three component mix of thioredoxin-L2 antigens elicits broadly neutralizing responses against oncogenic human papillomaviruses.
    Seitz H; Canali E; Ribeiro-Müller L; Pàlfi A; Bolchi A; Tommasino M; Ottonello S; Müller M
    Vaccine; 2014 May; 32(22):2610-7. PubMed ID: 24662712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of hybrid virus-like particles to enhance the immunogenicity of a broadly protective HPV vaccine.
    Tyler M; Tumban E; Peabody DS; Chackerian B
    Biotechnol Bioeng; 2014 Dec; 111(12):2398-406. PubMed ID: 24917327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of neutralizing antibodies by human papillomavirus vaccine generated in mammalian cells.
    Wu X; Ma X; Li Y; Xu Y; Zheng N; Xu S; Nawaz W; Wu Z
    Antib Ther; 2019 Apr; 2(2):45-53. PubMed ID: 33928221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A universal virus-like particle-based vaccine for human papillomavirus: longevity of protection and role of endogenous and exogenous adjuvants.
    Tumban E; Peabody J; Peabody DS; Chackerian B
    Vaccine; 2013 Sep; 31(41):4647-54. PubMed ID: 23933337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robust In Vitro and In Vivo Neutralization against Multiple High-Risk HPV Types Induced by a Thermostable Thioredoxin-L2 Vaccine.
    Seitz H; Ribeiro-Müller L; Canali E; Bolchi A; Tommasino M; Ottonello S; Müller M
    Cancer Prev Res (Phila); 2015 Oct; 8(10):932-41. PubMed ID: 26170394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capsid display of a conserved human papillomavirus L2 peptide in the adenovirus 5 hexon protein: a candidate prophylactic hpv vaccine approach.
    Wu WH; Alkutkar T; Karanam B; Roden RB; Ketner G; Ibeanu OA
    Virol J; 2015 Sep; 12():140. PubMed ID: 26362430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.